Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells
Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor 5 displaying (sub)micromolar inhibition against both targets. When tested in several cancer cell lines, the hybrid 5 impaired ce...
Gespeichert in:
| Veröffentlicht in: | ACS medicinal chemistry letters 2020-05, Vol.11 (5), p.977-983 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 983 |
|---|---|
| container_issue | 5 |
| container_start_page | 977 |
| container_title | ACS medicinal chemistry letters |
| container_volume | 11 |
| creator | Romanelli, Annalisa Stazi, Giulia Fioravanti, Rossella Zwergel, Clemens Di Bello, Elisabetta Pomella, Silvia Perrone, Clara Battistelli, Cecilia Strippoli, Raffaele Tripodi, Marco del Bufalo, Donatella Rota, Rossella Trisciuoglio, Daniela Mai, Antonello Valente, Sergio |
| description | Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor 5 displaying (sub)micromolar inhibition against both targets. When tested in several cancer cell lines, the hybrid 5 impaired cell viability at low micromolar level and in leukemia U937 and rhabdomyosarcoma RH4 cells provided G1 arrest, apoptotic induction, and increased differentiation, associated with an increase of acetyl-H3 and acetyl-α-tubulin and a decrease of H3K27me3 levels. In glioblastoma U87 cells, 5 hampered epithelial to mesenchymal transition by increasing the E-cadherin expression, thus proposing itself as a useful candidate for anticancer therapy. |
| doi_str_mv | 10.1021/acsmedchemlett.0c00014 |
| format | Article |
| fullrecord | <record><control><sourceid>acs_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7236245</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>d107382933</sourcerecordid><originalsourceid>FETCH-LOGICAL-a457t-8643e972a26b97428ec931053efd7636a80ea0b9cb32afff7c2614326bb6c5423</originalsourceid><addsrcrecordid>eNqFkc1OAyEUhYnRWP9ewfACo_wNzLgwqdNqTZq40Y0bwlCmxVCoQJv49k6tGrtyxQ33nO8m5wBwidEVRgRfK52WZqYXZulMzldII4QwOwAnuGZVUVaiPPwzD8BpSm8I8VoIdAwGlDBaMsxOwPvIJDv3MHTw3saUC-uLxqmU4GitHBy_Tsj1ZDRs4KNf2NbmEG_gnQ3bw1b3gqHOdmPzB1R-tl24MP_6H2-UW6tsg4fWw0Z5bSJsjHPpHBx1yiVz8f2egZf78XMzKaZPD4_NcFooVopcVJxRUwuiCG9rwUhldE0xKqnpZoJTripkFGpr3VKiuq4TmnDMaK9uuS4ZoWfgdsddrdttVMbnqJxcRbtU8UMGZeX-xtuFnIeNFIRywsoewHcAHUNK0XS_XozktgS5X4L8LqE3Xv69_Gv7Sb0XkJ2gB8i3sI6-D-I_6id5A5m0</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>ACS Publications</source><source>PubMed Central</source><creator>Romanelli, Annalisa ; Stazi, Giulia ; Fioravanti, Rossella ; Zwergel, Clemens ; Di Bello, Elisabetta ; Pomella, Silvia ; Perrone, Clara ; Battistelli, Cecilia ; Strippoli, Raffaele ; Tripodi, Marco ; del Bufalo, Donatella ; Rota, Rossella ; Trisciuoglio, Daniela ; Mai, Antonello ; Valente, Sergio</creator><creatorcontrib>Romanelli, Annalisa ; Stazi, Giulia ; Fioravanti, Rossella ; Zwergel, Clemens ; Di Bello, Elisabetta ; Pomella, Silvia ; Perrone, Clara ; Battistelli, Cecilia ; Strippoli, Raffaele ; Tripodi, Marco ; del Bufalo, Donatella ; Rota, Rossella ; Trisciuoglio, Daniela ; Mai, Antonello ; Valente, Sergio</creatorcontrib><description>Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor 5 displaying (sub)micromolar inhibition against both targets. When tested in several cancer cell lines, the hybrid 5 impaired cell viability at low micromolar level and in leukemia U937 and rhabdomyosarcoma RH4 cells provided G1 arrest, apoptotic induction, and increased differentiation, associated with an increase of acetyl-H3 and acetyl-α-tubulin and a decrease of H3K27me3 levels. In glioblastoma U87 cells, 5 hampered epithelial to mesenchymal transition by increasing the E-cadherin expression, thus proposing itself as a useful candidate for anticancer therapy.</description><identifier>ISSN: 1948-5875</identifier><identifier>EISSN: 1948-5875</identifier><identifier>DOI: 10.1021/acsmedchemlett.0c00014</identifier><identifier>PMID: 32435414</identifier><language>eng</language><publisher>United States: American Chemical Society</publisher><subject>Letter</subject><ispartof>ACS medicinal chemistry letters, 2020-05, Vol.11 (5), p.977-983</ispartof><rights>Copyright © 2020 American Chemical Society.</rights><rights>Copyright © 2020 American Chemical Society 2020 American Chemical Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-a457t-8643e972a26b97428ec931053efd7636a80ea0b9cb32afff7c2614326bb6c5423</citedby><cites>FETCH-LOGICAL-a457t-8643e972a26b97428ec931053efd7636a80ea0b9cb32afff7c2614326bb6c5423</cites><orcidid>0000-0001-9176-2382 ; 0000-0002-2241-607X ; 0000-0002-3097-0003</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://pubs.acs.org/doi/pdf/10.1021/acsmedchemlett.0c00014$$EPDF$$P50$$Gacs$$H</linktopdf><linktohtml>$$Uhttps://pubs.acs.org/doi/10.1021/acsmedchemlett.0c00014$$EHTML$$P50$$Gacs$$H</linktohtml><link.rule.ids>230,314,724,777,781,882,2752,27057,27905,27906,53772,53774,56719,56769</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32435414$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Romanelli, Annalisa</creatorcontrib><creatorcontrib>Stazi, Giulia</creatorcontrib><creatorcontrib>Fioravanti, Rossella</creatorcontrib><creatorcontrib>Zwergel, Clemens</creatorcontrib><creatorcontrib>Di Bello, Elisabetta</creatorcontrib><creatorcontrib>Pomella, Silvia</creatorcontrib><creatorcontrib>Perrone, Clara</creatorcontrib><creatorcontrib>Battistelli, Cecilia</creatorcontrib><creatorcontrib>Strippoli, Raffaele</creatorcontrib><creatorcontrib>Tripodi, Marco</creatorcontrib><creatorcontrib>del Bufalo, Donatella</creatorcontrib><creatorcontrib>Rota, Rossella</creatorcontrib><creatorcontrib>Trisciuoglio, Daniela</creatorcontrib><creatorcontrib>Mai, Antonello</creatorcontrib><creatorcontrib>Valente, Sergio</creatorcontrib><title>Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells</title><title>ACS medicinal chemistry letters</title><addtitle>ACS Med. Chem. Lett</addtitle><description>Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor 5 displaying (sub)micromolar inhibition against both targets. When tested in several cancer cell lines, the hybrid 5 impaired cell viability at low micromolar level and in leukemia U937 and rhabdomyosarcoma RH4 cells provided G1 arrest, apoptotic induction, and increased differentiation, associated with an increase of acetyl-H3 and acetyl-α-tubulin and a decrease of H3K27me3 levels. In glioblastoma U87 cells, 5 hampered epithelial to mesenchymal transition by increasing the E-cadherin expression, thus proposing itself as a useful candidate for anticancer therapy.</description><subject>Letter</subject><issn>1948-5875</issn><issn>1948-5875</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNqFkc1OAyEUhYnRWP9ewfACo_wNzLgwqdNqTZq40Y0bwlCmxVCoQJv49k6tGrtyxQ33nO8m5wBwidEVRgRfK52WZqYXZulMzldII4QwOwAnuGZVUVaiPPwzD8BpSm8I8VoIdAwGlDBaMsxOwPvIJDv3MHTw3saUC-uLxqmU4GitHBy_Tsj1ZDRs4KNf2NbmEG_gnQ3bw1b3gqHOdmPzB1R-tl24MP_6H2-UW6tsg4fWw0Z5bSJsjHPpHBx1yiVz8f2egZf78XMzKaZPD4_NcFooVopcVJxRUwuiCG9rwUhldE0xKqnpZoJTripkFGpr3VKiuq4TmnDMaK9uuS4ZoWfgdsddrdttVMbnqJxcRbtU8UMGZeX-xtuFnIeNFIRywsoewHcAHUNK0XS_XozktgS5X4L8LqE3Xv69_Gv7Sb0XkJ2gB8i3sI6-D-I_6id5A5m0</recordid><startdate>20200514</startdate><enddate>20200514</enddate><creator>Romanelli, Annalisa</creator><creator>Stazi, Giulia</creator><creator>Fioravanti, Rossella</creator><creator>Zwergel, Clemens</creator><creator>Di Bello, Elisabetta</creator><creator>Pomella, Silvia</creator><creator>Perrone, Clara</creator><creator>Battistelli, Cecilia</creator><creator>Strippoli, Raffaele</creator><creator>Tripodi, Marco</creator><creator>del Bufalo, Donatella</creator><creator>Rota, Rossella</creator><creator>Trisciuoglio, Daniela</creator><creator>Mai, Antonello</creator><creator>Valente, Sergio</creator><general>American Chemical Society</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0001-9176-2382</orcidid><orcidid>https://orcid.org/0000-0002-2241-607X</orcidid><orcidid>https://orcid.org/0000-0002-3097-0003</orcidid></search><sort><creationdate>20200514</creationdate><title>Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells</title><author>Romanelli, Annalisa ; Stazi, Giulia ; Fioravanti, Rossella ; Zwergel, Clemens ; Di Bello, Elisabetta ; Pomella, Silvia ; Perrone, Clara ; Battistelli, Cecilia ; Strippoli, Raffaele ; Tripodi, Marco ; del Bufalo, Donatella ; Rota, Rossella ; Trisciuoglio, Daniela ; Mai, Antonello ; Valente, Sergio</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-a457t-8643e972a26b97428ec931053efd7636a80ea0b9cb32afff7c2614326bb6c5423</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Letter</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Romanelli, Annalisa</creatorcontrib><creatorcontrib>Stazi, Giulia</creatorcontrib><creatorcontrib>Fioravanti, Rossella</creatorcontrib><creatorcontrib>Zwergel, Clemens</creatorcontrib><creatorcontrib>Di Bello, Elisabetta</creatorcontrib><creatorcontrib>Pomella, Silvia</creatorcontrib><creatorcontrib>Perrone, Clara</creatorcontrib><creatorcontrib>Battistelli, Cecilia</creatorcontrib><creatorcontrib>Strippoli, Raffaele</creatorcontrib><creatorcontrib>Tripodi, Marco</creatorcontrib><creatorcontrib>del Bufalo, Donatella</creatorcontrib><creatorcontrib>Rota, Rossella</creatorcontrib><creatorcontrib>Trisciuoglio, Daniela</creatorcontrib><creatorcontrib>Mai, Antonello</creatorcontrib><creatorcontrib>Valente, Sergio</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>ACS medicinal chemistry letters</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Romanelli, Annalisa</au><au>Stazi, Giulia</au><au>Fioravanti, Rossella</au><au>Zwergel, Clemens</au><au>Di Bello, Elisabetta</au><au>Pomella, Silvia</au><au>Perrone, Clara</au><au>Battistelli, Cecilia</au><au>Strippoli, Raffaele</au><au>Tripodi, Marco</au><au>del Bufalo, Donatella</au><au>Rota, Rossella</au><au>Trisciuoglio, Daniela</au><au>Mai, Antonello</au><au>Valente, Sergio</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells</atitle><jtitle>ACS medicinal chemistry letters</jtitle><addtitle>ACS Med. Chem. Lett</addtitle><date>2020-05-14</date><risdate>2020</risdate><volume>11</volume><issue>5</issue><spage>977</spage><epage>983</epage><pages>977-983</pages><issn>1948-5875</issn><eissn>1948-5875</eissn><abstract>Since the histone modifying enzymes EZH2 and HDACs control a number of epigenetic-dependent carcinogenic pathways, we designed the first-in-class dual EZH2/HDAC inhibitor 5 displaying (sub)micromolar inhibition against both targets. When tested in several cancer cell lines, the hybrid 5 impaired cell viability at low micromolar level and in leukemia U937 and rhabdomyosarcoma RH4 cells provided G1 arrest, apoptotic induction, and increased differentiation, associated with an increase of acetyl-H3 and acetyl-α-tubulin and a decrease of H3K27me3 levels. In glioblastoma U87 cells, 5 hampered epithelial to mesenchymal transition by increasing the E-cadherin expression, thus proposing itself as a useful candidate for anticancer therapy.</abstract><cop>United States</cop><pub>American Chemical Society</pub><pmid>32435414</pmid><doi>10.1021/acsmedchemlett.0c00014</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0001-9176-2382</orcidid><orcidid>https://orcid.org/0000-0002-2241-607X</orcidid><orcidid>https://orcid.org/0000-0002-3097-0003</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1948-5875 |
| ispartof | ACS medicinal chemistry letters, 2020-05, Vol.11 (5), p.977-983 |
| issn | 1948-5875 1948-5875 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7236245 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; ACS Publications; PubMed Central |
| subjects | Letter |
| title | Design of First-in-Class Dual EZH2/HDAC Inhibitor: Biochemical Activity and Biological Evaluation in Cancer Cells |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T02%3A25%3A58IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-acs_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Design%20of%20First-in-Class%20Dual%20EZH2/HDAC%20Inhibitor:%20Biochemical%20Activity%20and%20Biological%20Evaluation%20in%20Cancer%20Cells&rft.jtitle=ACS%20medicinal%20chemistry%20letters&rft.au=Romanelli,%20Annalisa&rft.date=2020-05-14&rft.volume=11&rft.issue=5&rft.spage=977&rft.epage=983&rft.pages=977-983&rft.issn=1948-5875&rft.eissn=1948-5875&rft_id=info:doi/10.1021/acsmedchemlett.0c00014&rft_dat=%3Cacs_pubme%3Ed107382933%3C/acs_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/32435414&rfr_iscdi=true |